JP Morgan Maintains Underweight on Enanta Pharma, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains an Underweight rating on Enanta Pharma (NASDAQ:ENTA) and lowers the price target from $11 to $10.
August 06, 2024 | 4:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan analyst Eric Joseph maintains an Underweight rating on Enanta Pharma and lowers the price target from $11 to $10.
The lowered price target and maintained Underweight rating by a major financial institution like JP Morgan is likely to negatively impact investor sentiment and short-term stock price of Enanta Pharma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100